|
Aug 09, 2021
|
BioCryst Commences Public Offering of Common Stock and Pre-Funded Warrants
|
|
|
Aug 05, 2021
|
BioCryst Reports Second Quarter 2021 Financial Results and Upcoming Key Milestones
|
|
|
Aug 03, 2021
|
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
|
Jul 28, 2021
|
BioCryst Appoints Vincent Milano to Board of Directors
|
|
|
Jul 22, 2021
|
BioCryst to Report Second Quarter 2021 Financial Results on August 5
|
|
|
Jul 15, 2021
|
BioCryst Announces Designs for REDEEM-1 and REDEEM-2 Pivotal Trials with BCX9930 as Oral Monotherapy for Patients with PNH
|
|
|
Jul 10, 2021
|
BioCryst Reports 96-week Data from APeX-2 Showing ORLADEYO®(berotralstat) Reduced HAE Attack Rate by 80 Percent from Baseline
|
|
|
Jul 01, 2021
|
ORLADEYO™ (berotralstat) Data to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress
|
|
|
Jun 16, 2021
|
BioCryst Announces Acceptance and Accelerated Review of the ORLADEYO™ (berotralstat) Marketing Application by the Israeli Ministry of Health
|
|
|
Jun 03, 2021
|
BioCryst Launches ORLADEYO™ (berotralstat) in Germany
|
|
